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Abstract: A majority of hypertensive patients need more than one antihypertensive drug to 
control their blood pressure. For this reason, most guidelines have introduced the possibility 
of prescribing fixed-dose combination therapies as first-line treatment in hypertension. Today, 
the concept of fixed-dose combinations has evolved and the term single pill combination might 
become more appropriate to reflect the large choice of drug combinations available on the 
market. Recently, a new single pill combination has been launched which combines the first 
direct renin inhibitor aliskiren and low doses of hydrochlorothiazide. This paper reviews the 
potential advantages of single pill combinations and presents the first results obtained with the 
aliskiren/HCTZ single pill combination in hypertension.
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Introduction
According to the most recent guidelines, the goal of hypertension management is to 
reduce blood pressure below 140/90 mmHg and to even lower targets in patients with a 
high cardiovascular risk in order to decrease the incidence of cardiovascular events such 
as stroke, myocardial infarction, congestive heart failure, and end stage renal disease 
and hence cardiovascular deaths.1,2 Numerous studies have demonstrated that to reach 
these target blood pressures physicians need to prescribe more than one antihypertensive 
agent.3,4 Thus, in the Antihypertensive and Lipid-Lowering treatment to prevent Heart 
Attack Trial (ALLHAT) study, 63% of the patients received 2 or more drugs to control 
their blood pressure.4 In the Hypertension Optimal Treatment (HOT) study, the average 
number of antihypertensive drugs to reach a diastolic blood pressure of 80 mmHg or less 
was greater than 3,5 and in the more recent ACCOMPLISH cohort, 74% of patients were 
receiving 2 antihypertensive agents or more at baseline, ie, before the administration of the 
tested combinations.6 These figures are also supported by the results of national surveys on 
hypertension indicating that most hypertensive patients need more than 2 antihypertensive 
drugs. For example, in a large unselected group of 2199 hypertensive patients managed 
in private practice in Switzerland, we reported recently that 50% of patients needed more 
than a combination therapy to achieve the desired blood pressure values.7
From fixed low-dose combinations  
to single pill combinations
In recent years, there has been a progressive shift from the classical step care approach 
to the use of combination therapies as first-line therapy.8 This change in paradigm has Integrated Blood Pressure Control 2010:3 58
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resulted from the evidence that although a single therapy is 
the preferred approach to treat hypertensive patients, this 
strategy is at best effective in correcting blood pressure 
in patients with stage I or II hypertension. Pragmatically, 
multiple-mechanism therapies should have a greater efficacy 
in controlling blood pressure in hypertensive patients, and it 
became rapidly obvious that with the use of combinations, 
a greater percentage of patients could indeed be brought to 
target more quickly. The increased efficacy of combination 
therapies reflects the fact that several pathophysiological 
mechanisms control blood pressure and that the likelihood 
of normalizing blood pressure is higher if more than one 
blood pressure control pathway is attacked. In addition, 
when combining therapeutic strategies, each component has 
the potential to neutralize counter-regulatory mechanisms 
and the development of potential side-effects, and the blood 
pressure-lowering effect is enhanced. One good example 
of such a synergism is the association of a blocker of the 
renin–angiotensin system (RAS) and a thiazide diuretic. The 
thiazide-induced natriuresis potentiates the antihypertensive 
efficacy of the RAS blocker by stimulating renin, whereas 
the RAS blocker limits the kaliuresis induced by the thiazide 
diuretic and therefore limits the incidence of hypokalemia.9
The concept of fixed-dose combinations started initially 
with low-dose combination because combining 2 drugs at 
low dose was found to increase the antihypertensive efficacy 
while reducing significantly the incidence of side-effects, 
hence leading to an improved tolerability profile.10 But the 
prescription of low dose combinations was justified when 
antihypertensive drugs were characterized by a dose-depen-
dent increase in side-effects. The concept was recently 
challenged with the introduction of angiotensin II receptor 
blockers (ARBs) which have a tolerability profile comparable 
to placebo even at higher doses.11 In this case, the use of low 
dose combinations is not really justified except possibly for 
the component of the combination with which the ARB is 
associated, ie, the diuretic or the calcium channel blocker. 
Thus the use of the generic term of “fixed low-dose combina-
tions” could be questioned. In a recent small survey, we have 
investigated the implementation of combination treatments of 
hypertension in general practice and whether “single pill com-
bination” would not be a better term to use than “fixed-dose 
combinations” (Burnier M, Neely P, unpublished poster, Am 
Soc Hypertens Meeting 2009; Figure 1). Indeed, single pill 
combination means that 2 or more drugs can be administered 
in a single pill whatever the dose. This formulation implies 
simplicity and flexibility. In contrast, the formulation fixed-
dose combinations implies that drugs are combined with a 
perception of lack of flexibility because of the term “fixed”. 
To investigate the perception of these formulations on the 
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Figure 1 Summary of the preference for the term single pill combination (SPC) versus fixed-dose combinations (FDC) among physicians interviewed in various countries. 
Single pill combination expresses the practice of giving 2 or more drugs in a single pill, which means simplicity and flexibility. In contrast, fixed-dose combinations reflects the 
fact that 2 drugs at fixed doses are combined, implying a simplified treatment but generally less flexibility because of the term “fixed”.Integrated Blood Pressure Control 2010:3 59
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field, 1-hour interviews were conducted with 76 general 
practitioners, 76 specialists, and 48 patients around the world. 
In all countries, specialists were more likely to use combina-
tions as first-line therapy than GPs, who tend to prescribe 
them only as a next step on from monotherapy. In this respect, 
the survey confirms a certain under-use of combination 
therapies considering the level of blood pressure control in 
the population.12 Interestingly, in all countries but Germany 
(Figure 1), the expression single pill combination was pre-
ferred mainly by patients and specialists and was found to 
create a more positive perception of combination products 
than fixed-dose combination, which gives the impression of 
being limited by the fixed component of the association. Thus, 
single pill combination could be proposed as the generic term 
to promote the use of combination therapies until the avail-
ability of the polypill, which combines therapeutic principles 
covering different diseases or risk factors.13
The other potential advantages  
of single pill combinations
Poor compliance and persistence are known to be major 
problems in all patients with chronic diseases and even more 
so when the disease is silent.14 It is estimated that 29% to 
58% of patients are non-persistent with therapy (persistence 
defined as remaining on treatment for 12 months) and 
24% to 51% are non-compliant (compliance defined as 
drugs available 80% of days in a year).15 In the US an 
estimated 14% of all prescriptions are never filled and an 
additional 13% are filled but never taken.16 Compliance 
and persistence appear to have an inverse relationship with 
time. A large retrospective cohort study of over 2000 new 
antihypertensive medication users over a 10-year period 
has illustrated this point and shown that the largest drop-
off occurs in the first years; among patients still in therapy 
after the first year, 50% stopped treatment within the next 
2 years.17
One of the major reasons why single pill combinations 
may provide greater benefits in terms of blood pressure 
control is certainly linked to drug adherence. Single pill com-
binations are likely to increase compliance and persistence 
because they simplify the treatment regimen and reduce the 
pill burden. Data are now accumulating to substantiate this 
hypothesis, and in a recent meta-analysis, non-compliance 
to study medication was reduced by around 25% in patients 
receiving a single pill combination versus free drug combi-
nations.18 In addition, with a low pill burden, patients have 
a different perception of their disease which may help to 
support their long-term adherence to therapy.
Single pill combinations are often advantageous over 
single agents in terms of tolerability. As discussed earlier, 
the occurrence of adverse effects associated with antihyper-
tensive drugs increases with higher drug doses except for 
ARBs. Single pill combinations are usually associated with 
lower doses of the individual components, which translates 
into a reduced likelihood of adverse events. Again, there is 
a wealth of data to support this statement. In a large meta-
analysis of 5 different categories of antihypertensive agents, 
the incidence of adverse effects with drug combinations was 
significantly less than additive, suggesting that antihyperten-
sive agents given in fixed-dose combinations do not potentiate 
the adverse effects of one another.10
The favorable impact of single pill combination thera-
pies on blood pressure control should contribute to reduce 
cardiovascular morbidity and mortality. This might in turn 
translate into reduced numbers of physician visits and hos-
pital admissions, shortened hospital stays, reduced non-drug 
and overall healthcare expenditure, and improved produc-
tivity. Thus, a wider use of single pill combinations could 
potentially reduce the overall cost of treatments.19 Whether 
this is indeed the case has not yet been proven definitively. 
Today, there are large variations among countries in the way 
single pill combination therapies are reimbursed and several 
financial barriers exist in some countries that limit a wider 
use of these combinations.
Aliskiren plus hydrochlorothiazide:  
a new single pill combination  
for hypertension
Direct renin inhibition (DRI) is a new way to interfere with 
the RAS, interrupting the enzymatic cascade at its first rate-
limiting step, ie, the conversion of angiotensinogen into 
angiotensin I by renin. In this class of agents, aliskiren is the 
first nonpeptide DRI which has been approved for the treat-
ment of hypertension in the US as well as in Europe.
Aliskiren is a transition-state mimetic agent with high 
hydrophilicity. This characteristic improves its oral bioavail-
ability which remains relatively low but is better than that 
of all earlier renin inhibitors and, in any case, sufficient to 
provide a sustained renin inhibition in humans.20 Aliskiren 
inhibits human renin with an IC50 of 0.6 nmol/L, and pre-
clinical data in salt-depleted normotensive and hypertensive 
animals have demonstrated that aliskiren is an effective blood 
pressure-lowering agent.21 Experimentally, aliskiren is as 
effective as other blockers of the RAS system in preventing 
atherosclerosis and cardiovascular and renal complications 
in models with an activated RAS.22,23Integrated Blood Pressure Control 2010:3 60
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In humans, aliskiren induces a dose-dependent inhibition 
of the RAS system in healthy volunteers20 as well as a 
dose-dependent decrease in blood pressure in hypertensive 
patients.24,25 Compared with other antihypertensive agents, 
aliskiren was found to be as effective in lowering blood pres-
sure as an angiotensin-converting enzyme (ACE) inhibitor, 
an ARB, or a beta-blocker, and in some instances, depending 
on the pharmacological characteristics of the comparator, 
aliskiren provided a more sustained effect on blood pres-
sure.24–27 This is due essentially to the particularly long 
duration of action of aliskiren which provides a sustained 
antihypertensive efficacy beyond 24 h thus lowering blood 
pressure even after a missed dose. When compared to a thia-
zide diuretic, aliskiren was found to provide a significantly 
greater reduction in blood pressure in a very large group of 
hypertensive patients.28
Similarly to ACE inhibitors and ARBs, aliskiren can 
be associated with a thiazide diuretic in order to increase 
its antihypertensive efficacy. As mentioned previously, the 
thiazide-induced salt depletion stimulates renin secretion, 
and hence blood pressure becomes more renin dependent. 
This was well demonstrated in a large study in which 
several doses of hydrochlorothiazide (HCTZ) and aliskiren 
were compared as single agents or in combinations.29 This 
study found a clear additive effect of the thiazide diuretic, 
which led to the development of single pill combinations 
of aliskiren and HCTZ (Figure 2). Additional randomized 
prospective studies have demonstrated that adding a thiazide 
diuretic in patients not responding to aliskiren alone or, 
conversely, adding aliskiren to a thiazide in non-responders 
to the diuretic provide significant additional blood pressure 
reductions.28,30–32 Thus, in obese patients who did not 
respond to a 4-week treatment of HCTZ, Jordan et al 
demonstrated that adding aliskiren could provide additional 
blood pressure-lowering efficacy while preserving an 
excellent tolerability profile.31 In this population, the 
addition of aliskiren to HCTZ was superior to adding a 
placebo to the diuretic but comparable to the addition 
of an ARB or a calcium channel blocker. However, the 
aliskiren/HCTZ combination was better tolerated than the 
CCB/HCTZ combination. Aliskiren has also been studied 
in patients not responding to the calcium channel blocker 
amlodipine. In this group of patients, adding aliskiren in 
patients receiving 5 mg of amlodipine was as effective as 
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Figure 2 Changes in mean sitting diastolic blood pressure (MSDBP) induced by increasing doses of aliskiren or hydrochlorothiazide (HCTZ) administered alone or in combination 
to hypertensive patients. Reproduced with permission from Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy 
when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–226.29 Copyright © 2007 wolters Kluwer Health.Integrated Blood Pressure Control 2010:3 61
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doubling the dose of amlodipine but was better tolerated as 
it induced less peripheral edema.30,33
Aliskiren single pill combinations: 
which will be the right one?
Today, aliskiren is available on many markets as single-agent 
therapy at doses of 150 mg and 300 mg as well as single-
pill combinations with HCTZ 12.5 mg and 25 mg. At these 
doses, aliskiren has been found to be effective and well toler-
ated, as summarized above. Using doses of aliskiren greater 
than 300 mg would increase the risk of developing diarrhea 
and, therefore, higher doses are not recommended. Studies 
have demonstrated that aliskiren could also be combined 
with a calcium channel blocker or with an ARB to enhance 
its antihypertensive efficacy and to provide organ protec-
tion.27,33 Thus, one question will soon arise: in which patient 
should a single pill combination be preferred to another 
one? Indeed, the recent results of the ACCOMPLISH trial 
have suggested that combining a blocker of the RAS system 
with a calcium channel blocker may be a better choice than 
combining a RAS blocker with a diuretic in patients with a 
high cardiovascular risk.6,27 This may be true for the specific 
population enrolled in this study, ie, mainly obese patients 
and patients with a metabolic syndrome and a very high 
cardiovascular risk profile. In these patients, the prescrip-
tion of a thiazide diuretic might actually increase the risk of 
developing diabetes. Therefore, diuretics should perhaps be 
prescribed as second- or third-line therapy in such patients. 
Nonetheless, single pill combination of a RAS blocker and 
a thiazide remains a very effective strategy to control blood 
pressure in a large proportion of the population. Thus, in a 
recent Canadian randomized controlled study, investigators 
compared a simplified algorithm for the treatment of hyper-
tension based on the initial use of a single pill combination 
of a diuretic and a RAS blocker with the conventional guide-
line-based care recommending a step-care approach.34 The 
initial use of single pill combinations was associated with 
a significantly higher proportion of patients achieving the 
target blood pressure (64.7 vs 52.7%). These results thus not 
only confirmed the superiority of single pill combinations 
over individual therapies but also confirm the usefulness of 
single pill combinations involving a thiazide diuretic and a 
RAS blocker in the management of hypertensive patients. 
The single pill combination of aliskiren and HCTZ is an 
effective alternative to the use of ACE inhibitors and ARBs 
associated with diuretics in hypertension. In the future, the 
availability of 2 single pill combinations involving aliskiren, 
one with HCTZ and another one with amlodipine, will 
provide all the possible alternatives to treat hypertensive 
patients.
Conclusions
Pragmatically, greater clinical use of single pill combinations 
could probably be very helpful in increasing the percentage 
of hypertensive patients with a well-controlled blood pres-
sure. Single pill combinations have several advantages over 
individual therapies, the most important a reduction of the 
pill burden and an improvement in long-term drug adherence. 
The excellent tolerability profile of single pill combinations 
involving a RAS blocker and a thiazide diuretic is another 
positive aspect that should be taken into account when pre-
scribing a new treatment. The recent development of the first 
direct renin inhibitor aliskiren, which is now also available 
as a single pill combination with HCTZ, represents a new 
opportunity to improve our ability to control blood pressure 
and to prevent target organ damage. Because of its efficacy 
and long-duration of action, aliskiren is an interesting alterna-
tive to ACE inhibitors and ARBs, and numerous large clinical 
trials are now ongoing to demonstrate its ability to provide 
organ protection and to reduce cardiovascular morbidity and 
mortality.35
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